

Terry Michael Fredeking

President – Antibody Systems, Inc.

President – Global Disease Research

In 1977 Terry Fredeking founded Antibody Systems, Inc. (ASI) a leading supplier of raw materials for diagnostic and therapeutic products for national and international pharmaceutical companies. ASI has participated in clinical research resulting in FDA approval for products such as Hepatitis B Vaccine, Cholera Vaccine, and Typhoid Vaccine.

Terry has been directly involved in researching treatments for diseases through Cooperative Research Agreements (CRADA) and collaborations with various government, private, and university laboratories in the United States.

The U.S. research has included HIV and Ebola Vaccines through a CRADA with the CDC level 4 labs and Ebola treatment research in level 4 labs at USAMRIID U.S. Army Ft. Dietrich Maryland.

Abroad he researched treatments for Tick Borne Encephalitis, Ebola, Marburg, Lassa, and Dengue Hemorrhagic Fever viruses through a CRADA with "Vector" a Russian level 4 lab in Siberia.

In Mexico a CRADA with the university of Mexico medical school in Merida and ASI, was focused on treatments of Dengue Hemorrhagic Fever in humans.

The company, Global Disease Research or GDR, was formed and received non-profit IRS 501c3 status on May 25, 2012 for the purpose of researching affordable and effective treatments for diseases. Terry Fredeking has served as President for that organization since inception.